![](https://investorshub.advfn.com/uicon/250952.png?cb=1618145303)
Wednesday, February 26, 2014 4:21:24 AM
For starters PPHM's business is not a static one. We have Cotara for brain Cancer in PIII approved ready to start with a partner, but Cotara is for ALL solid cancers.
So as it progressed over time it's investment cost and its value changed as we got PI, PII and finally interesting PIII approval with interim look-in and early trial stop possibility, Fast Track and US and Euro Orphan status. Certainly when the long term survivals became known the value changed again. Then comparing partnering Cotara which is at this moment restricted to Brain Cancer is a niche product, and expecting that it is a quick process is not the smartest thing to do. Certainly not in the light of what happened to PPHM in 2012 and the need to finance the company. This slows down everything.
But for Bavituximab it is even a completely different thing. It is like claiming you have land that holds a gold mine. In the beginning interested parties don't give much to partner because it isn't proven there is gold and all the digging still has to be done.
When some later you have a hole and provide some samples that hold some traces of gold the candidates may offer a little more because you did some digging but traces still isn't gold-mine grade. But you now are even more convinced that you have a gold mine so whatever they bid more, you levelled up your partnership price too.
In the next step you walk into artery of gold. Now your price goes up big time, but the candidates will say that the artery doesn't mean there is a gold mine on your land. In the back of their heads they know it doesn't really matter because they'll take the gold from the artery but it allows them to keep the offer low. You on the contrary are in "I told you!" mode.
Finally it looks like there is also silver, and some diamonds are found and the artery is getting larger and larger. The partnership candidates now start to regret they didn't jump on your initial order and they just hope you'll run out of money and will have to accept their offer any-ways. For there CEO's it is very hard to go back home and explain to the board why they didn't sign a contract with you at 100$ while now you ask 10000$ for exactly the same thing.
With Bavituximab it is exactly the same thing. First ONE condition (Breast) then it seems to work for others and you walk the FDA stairs from PI to PIII with another Fast Track granted, it seems to have applications in viral, in inflammatory, Digital Imaging, possibly even Alzheimer now, etc. The MOA gets better understood, it seems to be the ONLY upstream agent on the market, and improvement for MANY existing and also new anti-XYZ technology.
So wouldn't you think that the price gets UP as risk diminishes due to PPHM using our ATM money to pass the FDA approval, as the MOA gets better understood and Bavituximab's field of application broadens with time? Do you think that if you first asked for a 100 Milj upfront payment and now for 500 Milj a BP just swallows and says : OK!
By the way, that is why I always said that to a certain extend the ATM is not dilutive! As long as the money is leveraged. And now one would plead to give PPHM assets away or partner them quick & fast because it takes to long and in the process throw away that leverage that largely compensates money wise for the ATM dilution! That doesn't sound like a good dialogue to hold! First criticize the ATM and when one wants to get the maximum out of it and turn that into a win criticize that too!
So it is hard for the BP's, it is HARD because they see the missed opportunity and know PPHM was satisfied with getting 100 Milj$ up-front. And so, combined with the dose switching, parties leave the table and others came to the table. Others that think they can milk the cow better because a problem with it's milk was detected and assuming the cow will be happy to give it's milk thinking it may be sour anyway, while the partner know he can fix that.
Till past annual there were certain risks with the cow, but today the cow is in charge. Accusing King from not taking offers is simplistic. King, ES and the others try to get the MAXIMUM out of this, for them BUT at the same time for us.
I would be curious to see that if I made an offer on your house for 60% of its value that you would sell it to me because your concierge claims it would take to long to get a fair price. Right, it isn't his house, nor his money! In this PPHM case it is OUR money! Furthermore in your complete reasoning the words "fair offer" should have been key. But fair is a different thing depending on what side of the table you are sitting and what you know about Bavi's potential.
Sure King received offers! There is not even the beginning of a doubt about that. They don't even deny any more since the 24th FEB that Abbvie (ex Abbot Labs) was/has been sitting at the table. Man can we be glad that they didn't sign anything with what we know now about the MOA understanding. Possibly the dose switching did us a BIG favour, no matter how unfortunately that may have been for the time lost and no matter how strange that may sound as a statement!
So pls Mr King, ES, and friends TAKE ALL THE TIME YOU NEED TO DO IT RIGHT and get us the BEST PRICE for our shares!
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM